TITLE: Re-treatment with Direct Acting Antivirals for Chronic Hepatitis C Genotype 1: Emerging Evidence of Clinical Effectiveness and Safety An Update
|
|
- Hortense Howard
- 5 years ago
- Views:
Transcription
1 TITLE: Re-treatment with Direct Acting Antivirals for Chronic Hepatitis C Genotype 1: Emerging Evidence of Clinical Effectiveness and Safety An Update DATE: 02 January 2015 RESEARCH QUESTION What is the clinical effectiveness and safety of telaprevir, boceprevir, simeprevir or sofosbuvir and peginterferon + ribavirin (PR) combination treatments in patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior direct acting antiviral (DAA) plus (PR) therapy or PR therapy alone? KEY FINDINGS Four relevant conference abstracts of randomized controlled trials were identified regarding the clinical effectiveness and safety of triple therapy in patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior direct acting antiviral (DAA) plus (PR) therapy or PR therapy alone. METHODS A limited literature search was conducted on key resources including PubMed, EMBASE, The Cochrane Library (2014, Issue 12), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2014 and December 15, Internet links were provided, where available. Selection was limited to conference abstracts to capture emerging evidence regarding the retreatment of patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior DAA plus PR therapy or PR therapy alone. Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report. Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners own terms and conditions.
2 SELECTION CRITERIA One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1. Table 1: Selection Criteria Population Adult patients with CHC genotype 1 infection who have an inadequate response to DAA+PR therapy (due to virologic failure or intolerance) Intervention Telaprevir in combination with PR Boceprevir in combination with PR Simeprevir in combination with PR Sofosbuvir in combination with PR Comparator Comparisons between dual therapy (PR) vs. triple therapy (PR + DAA) Comparisons between DAA triple therapy options Outcomes SVR, treatment completion, histological changes, relapse, quality of life, liver failure, hepatocellular carcinoma, liver transplants, and mortality (allcause and liver related). Serious adverse events, adverse events, withdrawals due to adverse events, rash, fatigue, anemia, pruritus, anorectal discomfort, neutropenia, depression, suicidal ideation, and flu-like symptoms. Study Designs Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies CHC = chronic hepatitis C; DAA = direct acting antiviral; PR = peginterferon + ribavirin; SVR = sustained virological response. RESULTS Four relevant conference abstracts of randomized controlled trials were identified regarding the clinical effectiveness and safety of triple therapy in patients with chronic hepatitis C genotype 1 who have had an inadequate response to prior direct acting antiviral (DAA) plus (PR) therapy or PR therapy alone.no relevant conference abstracts of health technology assessments or systematic reviews were identified. OVERALL SUMMARY OF FINDINGS One abstract 1 was identified regarding a randomized controlled trial (RCT) that examined the safety and efficacy of boceprevir (BOC) in combination with peginterferon and ribavirin (PR) versus PR alone in patients in the Asia-Pacific region who had previously failed treatment for hepatitis C. At treatment week eight, hepatitis C virus was undetectable in 83.1% of patients in the BOC + PR group versus 47.2% in the PR group. The authors concluded that the safety of BOC + PR was similar for Korean patients as that reported in the North American studies. Three abstracts 2-4 were identified describing the ATTAIN trial which examined the safety and efficacy of simeprevir versus telaprevir, each in combination with PR for patients with hepatitis C who were partial or non-responders to previous PR therapy. Patients were stratified by genotype 1 subtype and by prior treatment response before randomization. 2 Mean patientreported outcomes (PRO) questionnaire scores worsened in both treatment groups by treatment week When examining the results of PRO questionnaires, no statistically significant difference in Fatigue Severity Scale (FSS) scores were reported between groups. 3 Based on the statistical analysis plan, the other patient-reported outcome endpoints were not examined due to the lack of significance for FSS. 3 The authors reported that the differences in FSS, depressive symptoms, skin symptoms, and quality of life were clinically meaningful in favor of simeprevir. 4 Re-treatment with DAAs for Hepatitis C Patients - Update 2
3 Fewer adverse events were reported in the simeprevir group. 3,4 The results of this trial will be published in the January 2015 issue of The Lancet Infectious Diseases. REFERENCES SUMMARIZED Health Technology Assessments No conference abstracts identified. Systematic Reviews and Meta-analyses No conference abstracts identified. Randomized Controlled Trials 1. Han KH, Helmond FA, Paik SW, Han SY, Heo J, Tak WY, et al. Boceprevir plus peginterferon alfa and ribavirin for Korean patients with chronic hepatitis C virus genotype 1 infection and previous treatment failure [abstract]. Hepatology International Conference: 23rd Conference of the Asian Pacific Association for the Study of the Liver, APASL 2014 Brisbane, QLD Australia Conference Start: Conference End: Conference Publication: (var pagings) 8 (1 Suppl (Presented at ; Conference Publication: (var.pagings). 8 (1 Suppl 1) ()(pp S222-S223), Date of Publication: March 2014.). OVID EMBASE Entry Week Summary: Addition of boceprevir (BOC) to peginterferon plus ribavirin (PR) significantly increased sustained virologic response (SVR) rates in patients from the Americas and Europe with hepatitis C virus (HCV) genotype (G)1 infection and previous treatment failure (PTF). The aim of this study is to explore the efficacy and safety of BOC + PR among patients in the Asia-Pacific region. Patients with HCV G1 infection and PTF were randomized to BOC + PR or PR. Patients randomized to BOC + PR received PR for 4 weeks then BOC + PR for 32 weeks. Patients with detectable HCV RNA at treatment week (TW)8 received a further 12 weeks of PR therapy. Patients randomized to PR received PR for 4 weeks then placebo + PR for 44 weeks. Patients with detectable HCV RNA at TW12 were discontinued. An interim analysis to assess TW8 response included patients from South Korea who reached TW12 or were discontinued before that time. In total, 107 Korean patients were enrolled. Most patients had previous relapse to PR with fewer prior null responders and prior partial responders. Undetectable HCV RNA at TW8 was higher among patients receiving BOC + PR compared with PR (83.1 vs 47.2 %) and this trend was consistent across prior response categories. Among patients receiving BOC + PR, TW8 response rates were slightly higher in noncirrhotic versus cirrhotic patients (85 vs 79 %); and in those with the IL28B CC genotype versus non-cc (90 vs 65 %). Approximately 83 % of patients receiving BOC + PR had undetectable HCV RNA at TW8, and would be eligible for short-duration response-guided therapy. Anemia, neutropenia, and adverse events leading to discontinuation or dose modification were more common in the boceprevir treatment arm. There were no deaths. In Korean patients with HCV G1 infection and PTF with PR, TW8 response rates are higher when retreated with BOC + PR versus PR. The safety profile of BOC + PR in Korean patients is consistent with the known safety profile of BOC + PR in Western patients. Background/aims: In the phase III RESPOND-2 study, addition of boceprevir (BOC) to peginterferon plus ribavirin (PR) significantly increased sustained virologic response (SVR) rates in patients from the Americas and Europe with hepatitis C Re-treatment with DAAs for Hepatitis C Patients - Update 3
4 virus (HCV) genotype (G)1 infection and previous treatment failure (PTF). Boceprevir response-guided therapy permits a shortened treatment duration of 36 weeks for PTF patients with undetectable HCV RNA at treatment week (TW)8. The aim of this study is to explore the efficacy and safety of BOC + PR among patients in the Asia-Pacific region. Methods: Patients in South Korea, Taiwan, and India with HCV G1 infection and PTF (PR for > 12 weeks) were randomized 2:1 to BOC + PR or PR. Patients randomized to BOC + PR received PR for 4 weeks then BOC + PR for 32 weeks. Patients with detectable HCV RNA at TW8 received a further 12 weeks of PR therapy. Patients randomized to PR received PR for 4 weeks then placebo + PR for 44 weeks. Patients with detectable HCV RNA at TW12 were discontinued. An interim analysis to assess TW8 response included patients from South Korea who reached TW12 or were discontinued before that time. Results from Korean patients are presented here. Results: In total, 107 Korean patients were enrolled (male, 63 %; IL28B CC, 71 %; baseline viral load < 800,000 IU/mL, 29 %; HCV G1b, 99 %; cirrhotic, 25 %). Most patients had previous relapse to PR (76 vs 14 % with prior null response and 9 % with prior partial response). Undetectable HCV RNA at TW8 was higher among patients receiving BOC + PR compared with PR (83.1 vs 47.2 %; between-group difference = 29 %, 95 % confidence interval = %) and this trend was consistent across prior response categories (Table). Among patients receiving BOC + PR, TW8 response rates were slightly higher in noncirrhotic versus cirrhotic patients (85 [44/52] vs 79 % [15/19]); and in those with the IL28B CC genotype versus non-cc (90 % [46/51] vs 65 % [13/20]). Approximately 83 % of patients receiving BOC + PR had undetectable HCV RNA at TW8 (59/71) and would be eligible for short-duration responseguided therapy. SVR24 data will be presented at the meeting. Safety summaries are based on a mean observation period of approximately 25 weeks/person in both arms (Table). There were no deaths. Conclusions: In Korean patients with HCV G1 infection and PTF with PR, TW8 response rates are higher when retreated with BOC + PR versus PR. The safety profile of BOC + PR in Korean patients is consistent with the known safety profile of BOC + PR in Western patients. (Table Presented). ATTAIN Study 2. Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C, et al. A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study [abstract]. Hepatology International Conference: 23rd Conference of the Asian Pacific Association for the Study of the Liver, APASL 2014 Brisbane, QLD Australia Conference Start: Conference End: Conference Publication: (var pagings) 8 (1 Suppl (Presented at ; Conference Publication: (var.pagings). 8 (1 Suppl 1) ()(pp S397), Date of Publication: March 2014.). OVID EMBASE Entry Week Introduction: Simeprevir (SMV, TMC435) is a one-pill, once-daily (QD), oral, hepatitis C virus (HCV) NS3/4A protease inhibitor (PI), with anti-viral activity against HCV genotypes 1, 2, 4, 5 and 6. SMV has been approved in Canada, Japan and the USA and is under regulatory review in Europe. The safety and efficacy of SMV (150 mg QD) has been evaluated in several multicentre Phase IIB/III studies in treatment-naive and -experienced patients with chronic HCV genotype 1 infection and compensated liver disease. Telaprevir (TVR) is an oral, twice- (BID) or three-times daily (TID) HCV NS3/4A PI with efficacy against HCV genotype 1 when used in combination with pegylated interferon plus ribavirin Re-treatment with DAAs for Hepatitis C Patients - Update 4
5 (PR). ATTAIN (NCT ) aimed to demonstrate the non-inferiority of SMV versus TVR when used in a triple-therapy regimen of a direct-acting antiviral agent plus PR. Materials and methods: Adults (N = 744) with chronic HCV genotype 1 infection and compensated liver disease who were partial or null responders to prior PR therapy were enrolled in this Phase III randomised, double-blind study. Patients were stratified by HCV genotype 1 subtype (1a, 1b, other) and prior treatment response (null or partial response) and were randomised (1:1) to treatment with either SMV 150 mg QD + PR or TVR 750 mg TID + PR for 12 weeks, followed by 36 weeks of PR alone. The primary efficacy endpoint was sustained virologic response 12 weeks after the planned end of treatment (SVR12). Secondary endpoints included SVR24, ontreatment failure, viral breakthrough or viral relapse. Quality of life was assessed using validated, patient-reported outcome questionnaires for fatigue (FSS), productivity (WPAI-Hepatitis C), depression (CESD) and health status (EQ-5D). Safety outcomes included adverse events (AEs) including AEs of clinical interest, serious AEs, and laboratory abnormalities. Results: Results from this head-to-head study are due in early 2014, and will be presented at the meeting. Conclusion: This is the first Phase III, randomised, doubleblind study to directly compare the efficacy, safety and tolerability of SMV versus TVR both in combination with PR in prior non-responder patients chronically infected with HCV genotype 1 and compensated liver disease. This study was funded by Janssen Pharmaceuticals. 3. Scott J, Cerri K, Sbarigia U, Corbett C, Fu M, Jessner W. Simeprevir with PegIFN/ribavirin for chronic HCV infection shortens time with patientreported symptoms and impairment in QoL: ATTAIN study results [abstract]. Journal of Viral Hepatitis Conference: Viral Hepatitis Congress 2014 Frankfurt Germany Conference Start: Conference End: Conference Publication: (var pagings) 21 ()(pp 25), 2014 Date of Publication: October (Presented at ; Conference Publication: (var.pagings). 21 ()(pp 25), Date of Publication: October 2014). OVID EMBASE Entry Week BACKGROUND: Fatigue, skin and depressive symptoms are common in chronic hepatitis C virus (HCV)-infected patients, and can impair functioning and quality of life (QoL). ATTAIN, a Phase III, randomised, double-blind study compared simeprevir (SMV) plus peginterferon/ribavirin (PR) versus telaprevir (TVR) plus PR in HCV genotype 1-infected patients with compensated liver disease who were null- or partialresponders to prior PR. Patientreported outcomes (PRO) provide the patient's perspective on HCV therapy. METHODS: Patients received SMV (150 mg once-daily) or TVR (750 mg three-times-daily) plus PR for 12 weeks, then PR alone for 36 weeks. Patients completed PRO questionnaires to rate severity of fatigue [Fatigue Severity Scale (FSS)], skin symptoms (Skindex-16), depressive symptoms [Center for Epidemiologic Studies Depression (CES-D)], work productivity and daily activity impairment (hepatitis C-specific version of Work Productivity and Activity Impairment score, WPAI) and QoL (EuroQoL 5 Dimension, EQ-5D) at baseline (BL) and throughout the study. PRO data analyses compared areaunder- the-curve (BL towk60, AUC 60 ; BL towk12, AUC 12 ). RESULTS: Mean scores for all PRO scores (763 patients, SMV = 379, TVR = 384) worsened in both groups from BL to Wk12, were generally stable from Wk16 to Wk48 and returned close to BL values from Wk60 onwards. As AUC60 analyses did not show a statistically significant difference between groups in FSS, treatment comparisons for other PRO endpoints were not analysed statistically in keeping with the hierarchical testing procedure specified in the statistical analysis Re-treatment with DAAs for Hepatitis C Patients - Update 5
6 plan. Post-hoc AUC 12 analyses significantly favoured SMV versus TVR for FSS (p = 0.003, clinically meaningful difference), WPAI Daily Activity Impairment (p = 0.022), EQ- 5D VAS (p < 0.001), and maximum Skindex-16 score (p = ). Trends for lower CES- D and WPAI Work Impairment scores were observed for AUC 12. There were fewer serious adverse events (AEs), treatment-related AEs, AEs leading to permanent stop and anaemia AEs (grade 3 and serious AEs) reported with SMV versus TVR. CONCLUSIONS: During the initial 12-Wk triple treatment period, patients on SMV/PR reported significantly less fatigue and skin symptoms, and less impairment in daily activities and QoL versus TVR/PR patients, consistent with the better safety profile of SMV versus TVR. Significant differences in AUC 12 in favour of SMV were not replicated in AUC 60 analyses due to longer PR therapy duration, which dominated the overall results. 4. Scott J, Corbett C, Gilles L, Wan G, Sbarigia U, Jessner W. Impact of simeprevir versus telaprevir triple therapy for chronic HCV infection on patient-reported outcomes in prior non-responders to peginterferon/ribavirin results from the phase III attain study [abstract]. Value in Health Conference: ISPOR 17th Annual European Congress Amsterdam Netherlands Conference Start: Conference End: Conference Publication: (var pagings) 17 (7) ()(pp A682), 2014 Date of Publication: November (Presented at ; Conference Publication: (var.pagings). 17 (7) ()(pp A682), Date of Publication: November 2014.). OVID EMBASE Entry Week Objectives: In ATTAIN, a Phase III, randomised, head-to-head comparison study of simeprevir versus telaprevir, both with peginterferon/ribavirin (PR), in HCV genotype 1- infected prior null or partial PR responders, simeprevir exhibited better safety and tolerability. In this analysis, the impact on patient-reported outcomes (PRO) was analysed. Methods: Patients received simeprevir (150mg QD) or telaprevir (750mg TID, 7-9hrs apart) +PR for 12wks followed by PR alone (36wks) in a double-blind, double-dummy design. PRO questionnaires, completed at baseline, throughout treatment and at follow-up, rated fatigue severity (FSS), depressive symptoms (CES-D), work and daily activities impairment (WPAI: Hepatitis-C), health-related quality of life (EQ-5D visual analogue scale), and skin symptoms (Skindex-16). During simeprevir/telaprevir treatment, between-treatment meanvalue differences were calculated using area-under-the curve to Wk12 (AUC12) for all measures except Skindex- 16 where maximum (worst) scores during the first 12 wks were used. Subgroup analyses evaluated the impact of SVR12, age, fibrosis and treatment completion. Results: Compared with normative studies, baseline PRO scores indicated greater fatigue, depressive symptoms and daily activities impairment. Mean PRO scores in both groups worsened during the first 12 weeks of treatment, remained stable through Week 48 and returned to values close to baseline at end of treatment. Clinically relevant between-treatment differences in FSS, CES-D, Skindex-16 and EQ-5D scores indicated less impairment with simeprevir than telaprevir. AUC12 betweentreatment differences significantly favoured simeprevir for FSS (p= 0.003), WPAI Activity Impairment (p= 0.022), and EQ-5D (p< 0.001). Mean Skindex-16 maximum total (p= ) and subscale scores were significantly lower for simeprevir. Subgroup analyses showed less impairment with simeprevir versus telaprevir on most PRO scores in patients who failed treatment, were > 45 years old or had advanced fibrosis. Conclusions: Simeprevir/PR resulted in less fatigue, depressive and skin-related symptoms and less impairment in daily activities than telaprevir/pr. These findings Re-treatment with DAAs for Hepatitis C Patients - Update 6
7 provide valuable information on the tolerability of these regimens from the patient perspective. Non-Randomized Studies No conference abstracts identified. PREPARED BY: Canadian Agency for Drugs and Technologies in Health Tel: Re-treatment with DAAs for Hepatitis C Patients - Update 7
Clinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta363
Ledipasvir sofosbuvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta363 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationTITLE: Discontinuation of Benzodiazepines and Other Sedative-Hypnotic Sleep Medication in Hospitalized Patients: Clinical Evidence and Guidelines
TITLE: Discontinuation of Benzodiazepines and Other Sedative-Hypnotic Sleep Medication in Hospitalized Patients: Clinical Evidence and Guidelines DATE: 25 September 2015 RESEARCH QUESTIONS 1. What is the
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationScottish Medicines Consortium
Scottish Medicines Consortium pegylated interferon α 2b (ViraferonPeg ), 50, 80, 100, 120 or 150 micrograms powder for solution for injection in pre-filled pen, in combination with ribavirin (Rebetol ),
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationAntiviral Drugs Advisory Committee Meeting. Briefing Document. Simeprevir (TMC435) Treatment of Patients with Chronic Hepatitis C NDA
ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE 1 Antiviral Drugs Advisory Committee Meeting Briefing Document Simeprevir (TMC435) Treatment of Patients with Chronic Hepatitis C NDA
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationC A D T H T H E R A P E U T I C R E V I E W
C A D T H T H E R A P E U T I C R E V I E W July 2015 [DRAFT FOR CONSULTATION] Drugs for Chronic Hepatitis C Infection: Clinical Review This report is prepared by the Canadian Agency for Drugs and Technologies
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationTreatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble
Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationAbbreviated Class Update: Hepatitis C
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFrom 19 February 2015
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment pharmaceuticals with new active ingredients, in accordance
More informationNew Treatments for HCV: Perspective From Asia
REVIEW New Treatments for HCV: Perspective From Asia Ming-Lung Yu, M.D., Ph.D.,*, Wan-Long Chuang, M.D., Ph.D.*, Introduction The prevalence and number of people with antibodies to hepatitis C virus (anti-hcv)
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 INCIVO 375 mg, film-coated tablet B/4 bottles of 42 tablets (CIP code: 217 378-5) B/1 bottle of 42
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationAssessment of sofosbuvir (Sovaldi )
Assessment of sofosbuvir (Sovaldi ) Summary of the national assessments of sofosbuvir (Sovaldi ) for the treatment of Hepatitis C December 18, 2014 Health Care Institute, Diemen, NL Lead Partner WP5 EUnetHTA
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationCommon Drug Review Clinical Review Report
Common Drug Review Clinical Review Report June 2015 Drug ombitasvir, paritaprevir, ritonavir and dasabuvir (Holkira Pak) Indication For the treatment of adults with genotype 1 chronic hepatitis C virus
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationGlecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1
Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,
More informationHTA: Models, Costs & Benefits.
HTA: Models, Costs & Benefits John.Cairns@lshtm.ac.uk Explicit evaluation of costs and benefits Advantages Potential for more consistent decision making Potential for more transparent decision making Facilitates
More informationTITLE: Hyperbaric Oxygen Therapy for Adults with Mental Illness: A Review of the Clinical Effectiveness
TITLE: Hyperbaric Oxygen Therapy for Adults with Mental Illness: A Review of the Clinical Effectiveness DATE: 27 August 2014 CONTEXT AND POLICY ISSUES Mental illness, including major depressive episode,
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364
Daclatasvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationPegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C
Liver International ISSN 1478-3223 REVIEW ARTICLE Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C Nicole M. Welch and Donald M. Jensen University
More informationOlysio (simeprivir) Policy Number: Last Review: 09/2017 Origination: 09/2013 Next Review: 09/2018
Olysio (simeprivir) Policy Number: 5.01.604 Last Review: 09/2017 Origination: 09/2013 Next Review: 09/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Olysio (simeprivir)
More informationOlysio PegIntron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.27 Subject: Olysio PegIntron Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio PegIntron
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio Pegasys
More informationA collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C
A collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C Jefferies Health Care Conference June 2013 Charlotte Edenius, EVP Development
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION DACLATASVIR (Daklinza Bristol-Myers Squibb Canada Inc.) Indication: Chronic Hepatitis C Genotype 1, 2, or 3 Infection in Adults Recommendation: The Canadian Drug Expert Committee
More informationSofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4
Phase 3 Treatment Experienced Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4 Bourlière M, et al. N Engl J Med. 217;376:2134-46. POLARIS-4: Study Features POLARIS-4 Trial Design:
More informationSAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed
More informationHorizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688
Horizon Scanning Centre November 2012 Faldaprevir with BI 207127 for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationTriple therapy with telaprevir or boceprevir: management of side effects
Triple therapy with telaprevir or boceprevir: management of side effects Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationledipasvir/sofosbuvir, 90mg/400mg, film-coated tablet (Harvoni ) SMC No. (1030/15) Gilead Sciences Ltd
ledipasvir/, 90mg/400mg, film-coated tablet (Harvoni ) SMC No. (1030/15) Gilead Sciences Ltd 06 February 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationPegylated Interferon Agents for Hepatitis C
Applicable X X X X X X X Pegylated Interferon Agents for Hepatitis C Override(s) Prior Authorization Quantity Limit Initial for Monotherapy or Combination with Ribavirin based on Genotype, Status, or Co-Infection
More informationHALLMARK-DUAL Study. Daclatasvir + Asunaprevir in Genotype 1b. Hepatitis. Treatment-Naïve and Treatment-Experienced
Phase 3 Treatment-Naïve and Treatment-Experienced Daclatasvir + Asunaprevir in Genotype 1b HALLMARK-DUAL Study Manns M, et al. Lancet. 2014;384:1597-605. Daclatasvir + Asunaprevir for HCV GT 1b HALLMARK-DUAL:
More informationHepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, 2014 ClinicalTrials.gov ID: NCT00372385 Study Identification Unique Protocol ID: VX05-950-104EU Brief Title:
More informationABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1
ABCs of Hepatitis C: What s New ACG Postgraduate Course Washington, DC October 30, 2011 Ira M. Jacobson, M.D. Vincent Astor Professor of Medicine Chief, Division of Gastronterology and Hepatology Medical
More informationVosevi (sofosbuvir/velpatasvir/voxilaprevir)
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Policy Number: 5.01.646 Last Review: 10/2017 Origination: 10/2017 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationM (SAPPHIRE-II)
PRESS RELEASE AbbVie Demonstrates 96 percent SVR 12 in its Phase III Study of Treatment- Experienced Patients with Genotype 1 Hepatitis C Results further confirm phase II studies, with consistent virologic
More informationGane et al. BMC Infectious Diseases (2017) 17:389 DOI /s
Gane et al. BMC Infectious Diseases (2017) 17:389 DOI 10.1186/s12879-017-2444-3 RESEARCH ARTICLE Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More information1.0 Abstract. Title. Keywords
1.0 Abstract Title Real World Evidence of the Effectiveness of Paritaprevir/r Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients with Chronic Hepatitis C - An Observational Study in Austria (REAL) Keywords
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationInformation Magazine for people with Hepatitis C and HIV. Hepatitis C - Treatment in people with haemophilia, the results to date
Positive News Information Magazine for people with Hepatitis C and HIV Hepatitis C - Treatment in people with haemophilia, the results to date From July 2012 to October 2013, a total of fifteen persons
More informationGenotype 1 Treatment Naïve No Cirrhosis Options
Genotype 1 Treatment Naïve No Cirrhosis Options Elbasvir/Grazoprevir (Zepatier ) x 12 weeks 1 Glecaprevir/Pibrentasvir (Mavyret ) x 8 weeks Ledipasvir/Sofosbuvir (Harvoni ) x 8-12 weeks 2 1 If genotype
More informationTITLE: Patient-Controlled Analgesia for Acute Injury Transfers: A Review of the Clinical Effectiveness, Safety, and Guidelines
TITLE: Patient-Controlled Analgesia for Acute Injury Transfers: A Review of the Clinical Effectiveness, Safety, and Guidelines DATE: 11 August 2014 CONTEXT AND POLICY ISSUES Patient-controlled analgesia
More informationOptimal Treatment with Boceprevir. Michael Manns
Optimal Treatment with Boceprevir Michael Manns 6th Paris Hepatitis Conference, 14th January 2013 Acknowledgements Benjamin Maasoumy Optimal Patient Selection Defining the Ideal Candidate Treatment Urgency
More informationABT-493, ABT-530, ABT-493/ABT-530 M Clinical Study Report Primary Analysis R&D/16/0160. Referring to Part of Dossier: Volume: Page:
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-493, ABT-530, ABT-493/ABT-530 Name of Active Ingredient: ABT-493: (3aR,7S,10S,12R,21E,24aR)- 7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1- methylcyclopropane-1-
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365
Ombitasvir paritaprevir ritonavir with or without dasabuvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365 NICE 2017. All rights reserved.
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationBoceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study
Ferrante et al. BMC Infectious Diseases 2013, 13:190 RESEARCH ARTICLE Open Access Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness
More informationDATE: 17 July 2012 CONTEXT AND POLICY ISSUES
TITLE: Sterile Pre-filled Saline Syringes for Acute Care Patients: A Review of Clinical Evidence, Cost-effectiveness, Evidence-based Guidelines, and Safety DATE: 17 July 2012 CONTEXT AND POLICY ISSUES
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationThe Pipeline of New HCV Therapies: What to Expect in the Next 5 Years. Nancy Reau, MD Associate Professor University of Chicago
The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years Nancy Reau, MD Associate Professor University of Chicago Learning Objectives Upon completion of this presentation, learners should
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationTITLE: Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines
TITLE: Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines DATE: 17 January 2014 CONTEXT AND POLICY ISSUES Obstructive sleep apnea (OSA) is a common
More informationCADTH THERAPEUTIC REVIEW Drugs for Chronic Hepatitis C Infection: Recommendations Report
CADTH THERAPEUTIC REVIEW Drugs for Chronic Hepatitis C Infection: Recommendations Report Product Line: Version: Volume Number: Issue Number: Publication Date: Report Length: Therapeutic Review 1.0 3 1d
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationTITLE: Naltrexone for the Treatment of Alcohol Dependence in Individuals with Co- Dependencies: A Review of the Clinical Effectiveness
TITLE: Naltrexone for the Treatment of Alcohol Dependence in Individuals with Co- Dependencies: A Review of the Clinical Effectiveness DATE: 08 October 2009 CONTEXT AND POLICY ISSUES: Poly-drug abuse is
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationTreatment with the New Direct Acting Antivirals for Hepatitis C
Treatment with the New Direct Acting Antivirals for Hepatitis C Mary Olson, DNP, ANP-BC Clinical Trials Program Director Weill Cornell Medical College The Center for the Study of Hepatitis C Objectives
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationClinical Applications of Resistance Stuart C. Ray, MD
Clinical Applications of Resistance Stuart C. Ray, MD Professor of Medicine and Oncology Director, Infectious Diseases Fellowship Training Program Johns Hopkins University School of Medicine Disclosures
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationTITLE: Probenecid Dosing When Given with Cefazolin: Guidelines and Clinical Effectiveness
TITLE: Probenecid Dosing When Given with Cefazolin: Guidelines and Clinical Effectiveness DATE: 21 November 2008 RESEARCH QUESTIONS: 1. What is the evidence for the clinical effectiveness of the 1g dose
More information